嘉实中证疫苗与生物技术ETF(562860)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-26,539,204.22 |
-61,285,525.57 |
-29,676,930.25 |
-103,382,387.94 |
| 本期利润 |
21,751,696.64 |
-125,561,444.57 |
-145,834,923.88 |
-182,594,622.93 |
| 加权平均基金份额本期利润 |
0.05 |
-0.24 |
-0.27 |
-0.21 |
| 本期加权平均净值利润率(%) |
8.04 |
-37.15 |
-39.09 |
-24.56 |
| 本期基金份额净值增长率(%) |
8.39 |
-27.47 |
-31.42 |
-16.16 |
| 期末可供分配利润 |
-129,172,213.05 |
-188,459,330.60 |
-221,405,762.76 |
-95,489,167.68 |
| 期末可供分配基金份额利润 |
-0.34 |
-0.39 |
-0.43 |
-0.16 |
| 期末基金资产净值 |
249,722,752.95 |
292,435,635.40 |
299,489,203.24 |
495,405,798.32 |
| 期末基金份额净值 |
0.66 |
0.61 |
0.58 |
0.84 |
| 基金份额累计净值增长率(%) |
-34.09 |
-39.19 |
-42.50 |
-16.16 |
微信公众号
证券之星APP
基本资料
